01- Post MI Betablockers for Good?
Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.
Read more HERE
02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports
This is one of the first papers documenting rare thrombotic effects related to the ChAdOx1 nCoV-19 vaccine in Austria and Germany. These effects may be a type of thrombocytopenia after inoculation with the vaccine developed by Oxford University and AstraZeneca.
Read more HERE
Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial and Deep Femoral Artery Recanalization”. This is the 6th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences and opinions, to keep advancing our knowledge in interventional cardiology.
Read more HERE
04- The Best Anticoagulant Agent for AF After TAVR
Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists.
Read more HERE
05- Short Therapy and Monotherapy, Plenty of Evidence
A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme.
Read more HERE
06- CT and Angiography Agreement in Patients from the ISCHEMIA Trial
Computed tomographic (CT) angiography showed a high degree of agreement with conventional angiography to detect significant coronary artery disease and rule out left main disease.
Read more HERE
07- IVUS vs OCT to Guide PCI: Which Should We Choose?
Controlling stent expansion with optical coherence tomography (OCT) based on an external elastic membrane–based protocol for stent sizing resulted non-inferior to the control group which used intravascular ultrasound (IVUS) and superior the angiography only group. Based on these study outcomes and the prior outcomes, we should use IVUS imaging if available.
Read more HERE
08- Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight
Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to death or MI reduction, pointing at its higher risk of bleeding vs. clopidogrel.
Read more HERE
09- TAVR vs. the Least Invasive Surgically Implanted Valve
Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR).
Read more HERE
10- Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines
The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
